Correction: MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment

Jun Yang; Chengde Liao; Yifan Liu; Guangjun Yang; Tengfei Ke; Yingying Ding; Qinqing Li

doi:10.18632/oncotarget.28217

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment

PDF | How to cite

Oncotarget. 2022; 13:641-641. https://doi.org/10.18632/oncotarget.28217

Metrics: PDF 656 views | ?

Jun Yang¹, Chengde Liao¹, Yifan Liu¹, Guangjun Yang¹, Tengfei Ke¹, Yingying Ding¹ and Qinqing Li¹

¹Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming 650118, Yunnan, P.R. China

Published: May 05, 2022

Copyright: © 2022 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4, panel ‘E’ contains an accidental duplication of panel ‘D’. The corrected Figure 4 (panels ‘D’ through ‘G’), is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:11964–11976. DOI: https://doi.org/10.18632/oncotarget.22600

Figure 4: Microvessel density and pericyte coverage in C6 glioma. (D–G) Immunohistochemical analysis representative examples of tumors on day 4 after bevacizumab treatment showed that a low density of microvasculature (CD34) and highly covered with perivascular cells (SMA) in the treatment group (E and G) on day 4 compared with control group (D and F). Images were acquired at 200× (D, E) or 100× (F, G) magnification. Scale = 50 μm.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28217

Publication Alerts

Corrections:

Correction: MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment